Marinomed Biotech AG (VIE:MARI)

Market Cap	33.79M
Revenue (ttm)	4.79M
Net Income (ttm)	-15.42M
Shares Out	1.78M
EPS (ttm)	-8.67
PE Ratio	n/a
Forward PE	1.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70
Average Volume	2,024
Open	19.00
Previous Close	19.00
Day's Range	19.00 - 19.00
52-Week Range	2.00 - 19.10
Beta	-0.10
RSI	70.96
Earnings Date	Sep 17, 2025

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 47
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: MARI

Financial Performance

In 2024, Marinomed Biotech AG's revenue was 4.79 million, a decrease of -49.01% compared to the previous year's 9.40 million. Losses were -15.42 million, 142.2% more than in 2023.